Ulinastatin
- Generic Name
- Ulinastatin
- Drug Type
- Biotech
- CAS Number
- 80449-31-6
- Unique Ingredient Identifier
- OR3S9IF86U
- Background
Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.
Ulinastatin Improves Post-Cardiac Surgery Cognitive Dysfunction
- Conditions
- Postoperative Cognitive DysfunctionPostoperative Delirium
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Qin Zhang
- Target Recruit Count
- 7065
- Registration Number
- NCT06268249
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Role of Ulinastatin in Preventing Severe Sepsis and Consequent Morbidities and Mortality
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Jinnah Postgraduate Medical Centre
- Target Recruit Count
- 175
- Registration Number
- NCT05895240
- Locations
- 🇵🇰
Medical ICU, Jinnah Postgraduate Medical Centre, Karachi, Sindh, Pakistan
Effect of Ulinastatin on the Action of NDMRs (Rocuronium / Cisatracurium)
- Conditions
- Nondepolarising Muscle Relaxants
- Interventions
- Procedure: TOF monitoring
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 80
- Registration Number
- NCT05716256
- Locations
- 🇨🇳
Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qin Zhang
- Target Recruit Count
- 236
- Registration Number
- NCT05534802
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05391789
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Jingan, Shanghai, China
Effects of Ulinastatin on Inflammatory Response During ECMO Support
- Conditions
- Inflammatory ResponseECMO
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 144
- Registration Number
- NCT04990752
- Locations
- 🇨🇳
Nangfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Protective Effect of Ulinastatin Against Negative Inflammatory Response and Organ Dysfunction After Acute Type a Aortic Dissection Surgery (PANDA I)
- Conditions
- Acute Aortic SyndromeType a Aortic Dissection
- Interventions
- Drug: Blank control
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Nanjing Medical University
- Target Recruit Count
- 203
- Registration Number
- NCT04711889
- Locations
- 🇨🇳
The first affiliated hospital of nanjing medical university, Nanjing, Jiangsu, China
🇨🇳Beijing Anzhen Hospital, Beijing, China
The Effect of Ulistin on Acute Renal Injury in Patients Undergoing OPCAB (Off Pump Coronary Artery Bypass): a Propensity Score Matched Study
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 500
- Registration Number
- NCT04473144
Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Stanford University
- Registration Number
- NCT04393311
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Protective Effect in Cardiac Surgery Patients
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT04028024
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.